Malignancy rates and comparisons to the general US population through 3 years in guselkumab-treated moderate-to-severe psoriasis patients in VOYAGE 1&2

被引：0
|
作者：
Papp, K. A. [1 ]
Reich, K. [2 ,3 ]
Gordon, K. B. [4 ]
Lebwohl, M. [5 ]
Song, M. [6 ]
Ramachandran, P. [7 ]
Randazzo, B. [6 ]
Shen, Y. -K. [6 ]
Blauvelt, A. [8 ]
机构：
[1] Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[2] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Ctr Translat Res Inflammatory Skin Disorders, Hamburg, Germany
[3] Skinflammat Ctr, Hamburg, Germany
[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Janssen Res & Dev LLC, Horsham, PA USA
[8] Oregon Med Res Ctr, Portland, OR USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [1] Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials
    Papp, Kim A.
    Reich, Kristian
    Gordon, Ken B.
    Kimball, Alexa B.
    Ramachandran, Paraneedharan
    Blauvelt, Andrew
    Lebwohl, Mark
    Song, Michael
    Randazzo, Bruce
    Shen, Yaung-Kaung
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [2] Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population
    Papp, Kim A.
    Reich, Kristian
    Gordon, Kenneth B.
    Lebwohl, Mark
    Song, Michael
    Miller, Megan
    Ramachandran, Paraneedharan
    Shen, Yaung-Kaung
    Lin, Connie B.
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB157 - AB157
  • [3] Malignancy rates through 5 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis: Results from the VOYAGE 1 and 2 trials and comparisons to general populations
    Blauvelt, Andrew
    Langley, Richard G.
    Ho, Vincent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB79 - AB79
  • [4] Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Lebwohl, Mark
    Langley, Richard G.
    Rowland, Katelyn
    Yang, Ya-Wen
    Chan, Daphne
    Miller, Megan
    You, Yin
    Yu, Jenny
    Thaci, Diamant
    Foley, Peter
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 274 - 282
  • [5] Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years
    Foley, Peter
    Reich, Kristian
    Blauvelt, Andrew
    Bagel, Jerry
    Langley, Richard
    Song, Michael
    Ramachandran, Paraneedharan
    Shen, Yaung-Kaung
    You, Yin
    Lebwohl, Mark
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [6] Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
    Reich, K.
    Papp, K. A.
    Armstrong, A. W.
    Wasfi, Y.
    Li, S.
    Shen, Y. K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1039 - 1049
  • [7] Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2
    Armstrong, A.
    Eyerich, K.
    Conrad, C.
    Zhu, Y.
    Yang, Y. -w.
    Miller, M.
    You, Y.
    Shen, Y. -k.
    Foley, P.
    Griffiths, C. E. M.
    Strober, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : E1375 - E1379
  • [8] Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab
    Cazana, Tamara Gracia
    Monroig, Josep Riera
    Izu, Rosa
    Yanguas, Ignacio
    Espes, Marta Lorda
    Salas, Maria Pilar Sanchez
    Gil, Miguel Fernando Garcia
    Bielsa, Alba Navarro
    Manrique, Beatriz Aldea
    Blasco, Manuel Almenara
    de Aranibar, Francisco Javier Garcia-Latasa
    Fuentelsaz, Victoria
    Callaghan, Ana Morales
    Ara-Martin, Mariano
    JAAD INTERNATIONAL, 2024, 16 : 66 - 71
  • [9] Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Song, Michael
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Han, Chenglong
    Blauvelt, Andrew
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 848 - 856
  • [10] Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years
    Gordon, Kenneth B.
    Merola, Joseph F.
    Foley, Peter
    Choi, Olivia
    Chan, Daphne
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Yang, Ya-Wen
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB163 - AB163
12345